Skip to main content
Premium Trial:

Request an Annual Quote

Accelr8 Shares Rise on Data Presentation

NEW YORK (GenomeWeb News) – Shares of Accelr8 Technology rose 51 percent in Thursday afternoon trade after the firm issued a release saying it had presented results on its rapid tests for identifying multi-resistant organisms at the recent 109th General Meeting of the American Society for Microbiology.

Accelr8 said that it reported results for its rapid test for identifying organisms that produce the new KPC antibiotic-destroying enzyme. "KPC is the first rapidly spreading resistance enzyme to emerge that attacks all members of the largest and most important antibiotic super-family," Accelr8 said in a statement.

The Denver-based firm did not provide further details from the study.

It also said that it reported additional results from a collaborative study with the Denver Health Medical Center on new tests for two additional multi-drug resistant bacteria, Pseudomonas aeruginosa and Acinetobacter baumannii. Accelr8 said that researchers using its BACcel prototypes in three different labs yielded accurate results in less than three hours as compared to the two to three days required for standard culturing tests.

Acceler8 also noted that it had received a new US patent covering its OptiChem technology for hydroxyl functional coatings.

In late Thursday trade on the New York Stock Exchange, shares of Accelr8 were up $1.07 at $3.16.

Filed under

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.